This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The objective was to systematically review the performance of 99m Tc-methoxyisobutylisonitrile ( 99m Tc-MIBI) imaging in the assessment of drug resistance in lung cancer and to analyse the cost-effectiveness of 99m Tc-MIBI imaging in the selection of lung cancer patients for chemotherapy.
Interventions
Three strategies were considered: basic supportive care (BSC); treatment for all patients; and the use of 99m Tc-MIBI to select patients for chemotherapy. The chemotherapy was assumed to be paclitaxel based.
Location/setting
UK/hospital.
Methods

Analytical approach:
This economic evaluation was based on a decision modelling framework. A short time horizon was necessary, given the poor survival of lung cancer patients. The authors stated that the perspective was that of the UK National Health Service (NHS).
Effectiveness data:
The clinical data for the accuracy of 99m Tc-MIBI imaging were derived from a systematic review, the key details of which were reported. MEDLINE was the main database searched and this was supplemented with data from other online databases. Case reports were excluded and only studies in which the initial imaging had been performed within 30 minutes of the tracer injection were included. A total of eight studies, with 235 patients, were selected and estimates from these studies were combined in a meta-analysis. The treatment effect for chemotherapy was mainly derived from randomised controlled trials (RCTs). The primary clinical estimate was the 99m Tc-MIBI imaging accuracy (its sensitivity and specificity).
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
Life-years (LYs) were the summary benefit measure. The expected survival was derived from clinical trials, which were part of a health technology assessment (HTA) for the NHS. This was adjusted for the prevalence of responders, which
